H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1

3 days ago 4

Maham Fatima

Thu, January 8, 2026 astatine 8:43 AM CST 2 min read

Structure Therapeutics Inc. (NASDAQ:GPCR) is 1 of the best up and coming stocks to bargain according to Wall Street. On December 19, H.C. Wainwright expert Ananda Ghosh raised the firm’s terms people connected Structure Therapeutics to $90 from $60 with a Buy standing connected the shares. The steadfast suggested that the company’s titration strategy has been validated by cardinal sentiment leaders. As payer economics propulsion oral GLP-1s toward Tier 1 therapy status, H.C. Wainwright views Structure Therapeutics’ existent valuation arsenic a important arbitrage accidental erstwhile compared to caller manufacture woody metrics. Due to beardown M&A imaginable and encouraging Phase 2 data, the institution is positioned for aboriginal maturation oregon acquisition.

Earlier connected December 12, Morgan Stanley expert Terence Flynn raised the firm’s terms people connected Structure Therapeutics to $125 from $120 portion keeping an Overweight standing connected the shares. Flynn informed investors that the regulatory and governmental uncertainties that weighed connected the biopharma assemblage successful 2025 are expected to slice successful 2026. This displacement is projected to redirect marketplace attraction toward the industry’s halfway concern show and pipeline developments alternatively than government-related risks.

H.C. Wainwright Upgrades Structure Therapeutics (GPCR) connected Massive Arbitrage Opportunity for Oral GLP-1

A time anterior to that, Jefferies besides raised the firm’s terms people connected the institution to $125 from $79 with a Buy standing connected the shares. The steadfast characterized the caller Phase 2b information for aleniglipron arsenic a coagulated win, positioning Structure Therapeutics Inc. (NASDAQ:GPCR) arsenic a person successful the space. Jefferies noted that the institution apt possesses a best-in-class small-molecule oral GLP1, supported by the astir precocious improvement signifier and objective information that has been importantly de-risked.

Structure Therapeutics Inc. (NASDAQ:GPCR) is simply a objective signifier planetary biopharmaceutical institution that develops and delivers caller oral small-molecule therapeutics to dainty assorted chronic diseases with unmet aesculapian needs successful the US.

While we admit the imaginable of GPCR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.